FTSE MIB
26.514,77 +615,20 (+2,38%) Dow Jones
32.244,58 +382,60 (+1,20%) Nasdaq
11.675,54 +45,02 (+0,39%) Nikkei 225
26.945,67 -388,12 (-1,42%) Petrolio
67,79 +0,15 (+0,22%) Bitcoin EUR
25.932,01 -333,41 (-1,27%)
Editas Medicine, Inc. (EDIT)
Preborsa:
| Chiusura precedente | 8,37 |
| Aperto | 8,37 |
| Denaro | 7,90 x 800 |
| Lettera | 9,63 x 800 |
| Min-Max giorno | 8,09 - 8,37 |
| Intervallo di 52 settimane | 7,48 - 21,59 |
| Volume | |
| Media Volume | 1.762.750 |
| Capitalizzazione | 565,556M |
| Beta (5 anni mensile) | 1,90 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -3,10 |
| Prossima data utili | 02 mag 2023 - 08 mag 2023 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 13,06 |
- GlobeNewswire
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linea Aspesi as Chief People Officer
Linea Aspesi Linea Aspesi, Executive Vice President and Chief People Officer, Editas Medicine CAMBRIDGE, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Linea Aspesi as the Company’s Executive Vice President and Chief People Officer. Ms. Aspesi will lead Editas’ human resources department and the Company’s people strategy in support of its mission and goals. “Our people and our culture are
- GlobeNewswire
Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates
Commenced parallel patient dosing in the EDIT-301 RUBY trial for SCD, following clinical proof-of-concept demonstrated last quarter On track to provide clinical update for RUBY trial by mid-2023 and dose 20 total patients by year-end On track to dose first patient in EDIT-301 EDITHAL trial for TDT in Q1 2023 and provide clinical update by year-end Entered into definitive agreement to sell iNK cell franchise and out-license certain gene editing technologies to Shoreline Biosciences CAMBRIDGE, Mas
- GlobeNewswire
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2022 Results and Corporate Update
CAMBRIDGE, Mass., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that it will host a conference call and webcast on Wednesday, February 22, 2023, at 8:00 a.m. ET to discuss results for the fourth quarter and full year of 2022 and to provide a corporate update. To access the conference call: U.S. callers should dial 877-407-0989 and international callers should dial 201-389-0921 approximately five minutes before the
